Skip to main content
main-content
Erschienen in: Current Colorectal Cancer Reports 2/2022

09.04.2022 | Systemic Therapies in Colorectal Cancer (SM Kazmi, Section Editor)

Current Updates on HER2–Directed Therapies in Metastatic Colorectal Cancer

verfasst von: Maria G. Fencer, Catherine H. Davis, Kristen R. Spencer

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Colorectal cancer is the third most common malignancy in the USA with 20% of patients presenting with metastatic disease. While first line agents include cytotoxic chemotherapy regimens, targeted therapies have an increasing role in the management of metastatic colorectal cancer (mCRC). Next Generation Sequencing (NGS) has expanded the ability to identify HER2 variations and is crucial to the next steps in personalized medicine.

Recent Findings

Anti-HER2 therapies provide a promising treatment option for patients who have exhausted traditional regimens including those who have failed prior anti-HER2 therapy. This is in accordance with the 2021 addition of trastuzumab-deruxtecan to the National Comprehensive Cancer Center Guidelines as a subsequent therapy in eligible patients based on the results of the DESTINY-CRC01 trial.

Summary

Various anti-HER2 therapies are approved alone or in combination for patients with mCRC and HER2–amplified tumors. Further investigation into the role of HER2–directed therapy in mutated mCRC is an unmet need, as is the wider use of NGS and ctDNA to explore mechanisms of resistance.
Literatur
26.
Zurück zum Zitat • Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358–73. https://​doi.​org/​10.​1002/​cncr.​31125. Lays out the differences between HER2 amplification and HER2 mutations and demonstrates the incidence of their association with other common alterations such as TP53, KRAS, and MSI. CrossRefPubMed • Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358–73. https://​doi.​org/​10.​1002/​cncr.​31125. Lays out the differences between HER2 amplification and HER2 mutations and demonstrates the incidence of their association with other common alterations such as TP53, KRAS, and MSI. CrossRefPubMed
35.
Zurück zum Zitat •• Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779–89. https://​doi.​org/​10.​1016/​S1470-2045(21)00086-3. This is the most recent updated data presented at ASCO regarding the results of trastuzumab-deruxetan which was recently approved by the FDA in 2021 for the treatment of mCRC and was added to the 2021 guidelines. CrossRefPubMed •• Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021;22(6):779–89. https://​doi.​org/​10.​1016/​S1470-2045(21)00086-3. This is the most recent updated data presented at ASCO regarding the results of trastuzumab-deruxetan which was recently approved by the FDA in 2021 for the treatment of mCRC and was added to the 2021 guidelines. CrossRefPubMed
44.
Zurück zum Zitat • Okamoto W, Nakamura Y, Kato T, et al. Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602). J Clin Oncol. 2021;39(15_suppl):3555–3555. https://​doi.​org/​10.​1200/​JCO.​2021.​39.​15_​suppl.​3555. Most recent updates published regarding the TRIUMPH trial which helped demonstrate the efficacy of ctDNA when compared the standard of care (tissue biopsy) at identifying HER2 status and subsequent treatment response. CrossRef • Okamoto W, Nakamura Y, Kato T, et al. Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602). J Clin Oncol. 2021;39(15_suppl):3555–3555. https://​doi.​org/​10.​1200/​JCO.​2021.​39.​15_​suppl.​3555. Most recent updates published regarding the TRIUMPH trial which helped demonstrate the efficacy of ctDNA when compared the standard of care (tissue biopsy) at identifying HER2 status and subsequent treatment response. CrossRef
45.
Zurück zum Zitat • Yoshino T, Bartolomeo MD, Raghav KPS, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). J Clin Oncol. 2021;39(15_suppl):3505–3505. https://​doi.​org/​10.​1200/​JCO.​2021.​39.​15_​suppl.​3505. This is the most recent updated data presented at ASCO regarding the results of trastuzumab-deruxetan which was recently approved by the FDA in 2021 for the treatment of mCRC and was added to the 2021 guidelines. CrossRef • Yoshino T, Bartolomeo MD, Raghav KPS, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). J Clin Oncol. 2021;39(15_suppl):3505–3505. https://​doi.​org/​10.​1200/​JCO.​2021.​39.​15_​suppl.​3505. This is the most recent updated data presented at ASCO regarding the results of trastuzumab-deruxetan which was recently approved by the FDA in 2021 for the treatment of mCRC and was added to the 2021 guidelines. CrossRef
46.
Metadaten
Titel
Current Updates on HER2–Directed Therapies in Metastatic Colorectal Cancer
verfasst von
Maria G. Fencer
Catherine H. Davis
Kristen R. Spencer
Publikationsdatum
09.04.2022
Verlag
Springer US
Erschienen in
Current Colorectal Cancer Reports / Ausgabe 2/2022
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-022-00475-0

Neu im Fachgebiet Onkologie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.